二甲双胍与胰岛素在2型糖尿病妊娠中的重大先天畸形风险:一项北欧登记队列研究
该北欧登记队列研究纳入4,023例2型糖尿病妊娠单胎婴儿,比较妊娠早期暴露于二甲双胍或胰岛素的重大先天畸形风险。任何二甲双胍暴露组畸形147例(4.7%),胰岛素单药组50例(5.7%),校正RR 0.84(95%CI 0.46-1.54);心脏畸形相应RR为1.01(95%CI 0.55-1.84)。作者结论为未发现二甲双胍较胰岛素增加畸形风险的证据,但因缺乏血糖控制信息,结果需谨慎解读。
要点
- 任何二甲双胍暴露与胰岛素单药相比,重大畸形校正RR 0.84(95%CI 0.46-1.54)。
- 二甲双胍单药与二甲双胍联合胰岛素的心脏畸形RR分别为0.92和1.72,95%CI均跨1。
- 作者结论为未发现二甲双胍较胰岛素增加畸形风险,但因缺乏血糖控制信息需谨慎解读。
核心结论
- 在2型糖尿病妊娠中,未发现妊娠早期暴露于二甲双胍较胰岛素增加重大先天畸形风险的证据,但因缺乏血糖控制信息,结果需谨慎解读。
研究设计与样本
- 北欧四国全国性登记队列研究,纳入妊娠早期器官发生期暴露于二甲双胍或胰岛素的活产及死产单胎婴儿4,023例。
- 主要排除标准为1型糖尿病、多囊卵巢综合征、助孕治疗及暴露于其他降糖药。
- 估计任何畸形及心脏畸形的校正风险比(RR)及95%CI。
主要发现
- 任何二甲双胍暴露(单用或联合胰岛素)组3,145例中147例(4.7%)诊断畸形,胰岛素单药组878例中50例(5.7%)诊断畸形,校正RR 0.84(95%CI 0.46-1.54)。
- 二甲双胍单药组2,852例中127例(4.4%)有畸形,二甲双胍联合胰岛素组293例中20例(6.8%)有畸形。
- 与胰岛素单药相比,二甲双胍单药畸形校正RR 0.83(95%CI 0.44-1.58),二甲双胍联合胰岛素0.98(95%CI 0.56-1.69)。
- 心脏畸形相应RR:任何二甲双胍1.01(95%CI 0.55-1.84),二甲双胍单药0.92(95%CI 0.47-1.81),二甲双胍联合胰岛素1.72(95%CI 0.76-3.91)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出缺乏血糖控制信息,结果应谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the risk of major congenital malformations with metformin versus insulin in pregnancies with type 2 diabetes. RESEARCH DESIGN AND METHODS: This cohort study used four Nordic countries' nationwide registers of live and stillborn infants exposed to metformin or insulin during first trimester organogenesis. Main exclusion criteria were type 1 diabetes, polycystic ovary syndrome, fertility treatment, and exposure to other diabetes drugs. Adjusted risk ratios (RRs) and 95% CIs were estimated for any and cardiac malformations. RESULTS: Of 3,734,125 infants in the source population, 25,956 were exposed to metformin or insulin in the first trimester, and 4,023 singleton infants were included. A malformation was diagnosed in 147 (4.7%) of 3,145 infants with exposure to any metformin (alone or in addition to insulin) and 50 (5.7%) of 878 infants with exposure to insulin alone (RR 0.84, 95% CI 0.46-1.54). Among 2,852 infants exposed to metformin alone and 293 infants exposed to metformin in addition to insulin 127 (4.4%) and 20 (6.8%), respectively, had a malformation. The adjusted risk was not increased for either metformin alone (0.83, 0.44-1.58) or both metformin and insulin (0.98, 0.56-1.69) versus insulin alone. Corresponding RRs for cardiac malformations were 1.01 (0.55-1.84) for any metformin, 0.92 (0.47-1.81) for metformin alone, and 1.72 (0.76-3.91) for both metformin and insulin. CONCLUSIONS: No evidence of an increased malformation risk with metformin versus insulin in the first trimester was found. Results should be interpreted with caution since information on glycemic control was missing.
引用
- Kjerpeseth LJ, Cesta CE, Furu K, et al. Metformin Versus Insulin and Risk of Major Congenital Malformations in Pregnancies With Type 2 Diabetes: A Nordic Register-Based Cohort Study. Diabetes Care. 2023. PMID: 37343541. doi:10.2337/dc23-0256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。